OTLK logo

Outlook Therapeutics (OTLK) Cash From Operations

Annual CFO

-$68.79 M
-$25.82 M-60.08%

September 30, 2024

Summary

Performance

1-Year Change

-60.08%

3-Year Change

-26.8%

5-Year Change

-113.05%

15-Year Change

-343.69%

OTLK Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

20.86%
OTLK annual cash flow from operations is higher than 20.86% of companies in Healthcare sector

High & Low

All-time High

-$7.02 M

3-Year Low

-$68.79 M
OTLK annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Sep 30, 2024
OTLK previous annual earnings announcement was published on Sep 30, 2024

Next Annual Earnings Report Date

N/A
OTLK next annual earnings announcement has not yet been scheduled

OtherOTLKcash flowmetrics:

Annual CFI

-
OTLK annual cash flow from investing activities value is unknown

Annual CFF

$60.33 M
OTLK annual cash flow from financing activities is $60.33 million

Annual FCF

-$68.79 M
OTLK annual free cash flow is -$68.79 million

Annual CAPEX

-
OTLK annual capital expenditures value is unknown

Quarterly CFO

-$10.97 M
+$6.01 M+35.42%

December 31, 2024

Summary

Performance

3-Month Change

+35.42%

1-Year Change

+35.42%

3-Year Change

+48.02%

5-Year Change

-54.84%

OTLK Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

30.41%
OTLK quarterly cash flow from operations is higher than 30.41% of companies in Healthcare sector

High & Low

All-time High

$79.90 K
OTLK quarterly cash flow from operations is currently <-9900.00% below its historical high of $79.90 thousand

3-Year Low

-$21.10 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
OTLK previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 16, 2025
OTLK next earnings announcement is scheduled for May 16, 2025

OtherOTLKcash flowmetrics:

Quarterly CFI

-
OTLK quarterly cash flow from investing activities value is unknown

Quarterly CFF

$1.74 M
OTLK quarterly cash flow from financing activities is $1.74 million

Quarterly FCF

-$10.97 M
OTLK quarterly free cash flow is -$10.97 million

Quarterly CAPEX

-
OTLK quarterly capital expenditures value is unknown

TTM CFO

-$66.73 M
+$2.06 M+3.00%

December 31, 2024

Summary

Performance

3-Month Change

+3%

1-Year Change

+3%

3-Year Change

-20.42%

5-Year Change

-122.39%

OTLK TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

23.43%
OTLK TTM cash flow from operations is higher than 23.43% of companies in Healthcare sector

High & Low

All-time High

-$3.67 M

3-Year Low

-$68.79 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
OTLK previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 16, 2025
OTLK next earnings announcement is scheduled for May 16, 2025

OtherOTLKcash flowmetrics:

TTM CFI

-
OTLK TTM cash flow from investing activities value is unknown

TTM CFF

$62.07 M
OTLK TTM cash flow from financing activities is $62.07 million

TTM FCF

-$66.73 M
OTLK TTM free cash flow is -$66.73 million

TTM CAPEX

-
OTLK TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

OTLK Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-60.1%+35.4%+3.0%
3 y3 years-26.8%+48.0%-20.4%
5 y5 years-113.0%-54.8%-122.4%

OTLK Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-60.1%at low-35.2%+48.0%-64.8%+3.0%
5 y5-year-116.4%at low-84.2%+48.0%-160.1%+3.0%
alltimeall time-879.9%at low<-9999.0%+48.0%-1720.0%+3.0%

Outlook Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-
-$10.97 M(-35.4%)
-$66.73 M(-3.0%)
Sep 2024
-$68.79 M(+60.1%)
-$16.98 M(-13.0%)
-$68.79 M(+6.6%)
Jun 2024
-
-$19.51 M(+1.3%)
-$64.55 M(+10.8%)
Mar 2024
-
-$19.27 M(+47.8%)
-$58.26 M(+23.7%)
Dec 2023
-
-$13.03 M(+2.3%)
-$47.10 M(+9.6%)
Sep 2023
-$42.97 M(-24.2%)
-$12.74 M(-3.6%)
-$42.97 M(+6.2%)
Jun 2023
-
-$13.22 M(+62.9%)
-$40.48 M(-16.3%)
Mar 2023
-
-$8.11 M(-8.8%)
-$48.37 M(-11.4%)
Dec 2022
-
-$8.90 M(-13.2%)
-$54.59 M(-3.7%)
Sep 2022
-$56.67 M(+4.5%)
-$10.25 M(-51.4%)
-$56.67 M(+2.3%)
Jun 2022
-
-$21.10 M(+47.2%)
-$55.41 M(+1.7%)
Mar 2022
-
-$14.33 M(+30.4%)
-$54.51 M(+5.0%)
Dec 2021
-
-$10.99 M(+22.2%)
-$51.92 M(-4.3%)
Sep 2021
-$54.25 M(+70.7%)
-$8.99 M(-55.5%)
-$54.25 M(-5.4%)
Jun 2021
-
-$20.19 M(+71.9%)
-$57.34 M(+33.0%)
Mar 2021
-
-$11.75 M(-11.8%)
-$43.10 M(+12.1%)
Dec 2020
-
-$13.32 M(+10.3%)
-$38.44 M(+20.9%)
Sep 2020
-$31.79 M(-1.5%)
-$12.08 M(+102.8%)
-$31.79 M(+23.9%)
Jun 2020
-
-$5.96 M(-15.9%)
-$25.65 M(-14.5%)
Mar 2020
-
-$7.08 M(+6.1%)
-$30.01 M(+2.8%)
Dec 2019
-
-$6.67 M(+12.3%)
-$29.18 M(-9.6%)
DateAnnualQuarterlyTTM
Sep 2019
-$32.29 M(-2.3%)
-$5.94 M(-42.3%)
-$32.29 M(-7.1%)
Jun 2019
-
-$10.31 M(+64.7%)
-$34.74 M(+5.4%)
Mar 2019
-
-$6.26 M(-36.0%)
-$32.97 M(-3.5%)
Dec 2018
-
-$9.78 M(+16.5%)
-$34.15 M(+3.4%)
Sep 2018
-$33.04 M(+113.1%)
-$8.39 M(-1.7%)
-$33.04 M(+34.5%)
Jun 2018
-
-$8.54 M(+14.7%)
-$24.57 M(+13.4%)
Mar 2018
-
-$7.44 M(-14.2%)
-$21.66 M(+18.2%)
Dec 2017
-
-$8.67 M(<-9900.0%)
-$18.33 M(+18.2%)
Sep 2017
-$15.51 M(-65.9%)
$79.90 K(-101.4%)
-$15.51 M(-40.3%)
Jun 2017
-
-$5.63 M(+37.0%)
-$25.96 M(-28.6%)
Mar 2017
-
-$4.11 M(-29.6%)
-$36.36 M(-7.5%)
Dec 2016
-
-$5.84 M(-43.7%)
-$39.31 M(-13.6%)
Sep 2016
-$45.48 M(+65.5%)
-$10.37 M(-35.4%)
-$45.48 M(-1.4%)
Jun 2016
-
-$16.04 M(+127.3%)
-$46.13 M(+15.0%)
Mar 2016
-
-$7.06 M(-41.2%)
-$40.12 M(+12.0%)
Dec 2015
-
-$12.01 M(+9.1%)
-$35.82 M(+30.4%)
Sep 2015
-$27.48 M(+291.4%)
-$11.01 M(+9.7%)
-$27.48 M(+66.9%)
Jun 2015
-
-$10.04 M(+263.6%)
-$16.46 M(+156.2%)
Mar 2015
-
-$2.76 M(-24.7%)
-$6.43 M(+75.3%)
Dec 2014
-
-$3.67 M
-$3.67 M
Sep 2014
-$7.02 M
-
-

FAQ

  • What is Outlook Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Outlook Therapeutics?
  • What is Outlook Therapeutics annual CFO year-on-year change?
  • What is Outlook Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Outlook Therapeutics?
  • What is Outlook Therapeutics quarterly CFO year-on-year change?
  • What is Outlook Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Outlook Therapeutics?
  • What is Outlook Therapeutics TTM CFO year-on-year change?

What is Outlook Therapeutics annual cash flow from operations?

The current annual CFO of OTLK is -$68.79 M

What is the all time high annual CFO for Outlook Therapeutics?

Outlook Therapeutics all-time high annual cash flow from operations is -$7.02 M

What is Outlook Therapeutics annual CFO year-on-year change?

Over the past year, OTLK annual cash flow from operations has changed by -$25.82 M (-60.08%)

What is Outlook Therapeutics quarterly cash flow from operations?

The current quarterly CFO of OTLK is -$10.97 M

What is the all time high quarterly CFO for Outlook Therapeutics?

Outlook Therapeutics all-time high quarterly cash flow from operations is $79.90 K

What is Outlook Therapeutics quarterly CFO year-on-year change?

Over the past year, OTLK quarterly cash flow from operations has changed by +$6.01 M (+35.42%)

What is Outlook Therapeutics TTM cash flow from operations?

The current TTM CFO of OTLK is -$66.73 M

What is the all time high TTM CFO for Outlook Therapeutics?

Outlook Therapeutics all-time high TTM cash flow from operations is -$3.67 M

What is Outlook Therapeutics TTM CFO year-on-year change?

Over the past year, OTLK TTM cash flow from operations has changed by +$2.06 M (+3.00%)